Looks like no one added any tags here yet for you.
active pharmaceutical ingredients
Must be formulated in dosage forms suitable for handling, distribution and administration to patients
pre formulation studies
This refers to the investigations pertaining to various physical and chemical properties of the drug substance
synthetic drugs
are weak acids OR weak bases
solubility dissolution rate stability particle size morphology
issues commonly arising in drug development
solubility
Measured by determining the concentration of the compound in solution after equilibrium
dissolution rate
Rate or speed at which a drug substance dissolves in a medium
high solubility high permeability
class 1
low solubility high permeability
class 2
high solubility low permeability
class 3
low solubility low permeability
class 4
dissolution rate
In drug design, it is intentionally manipulated by including different polymers to produce "slow-release" (for some drugs)
intrinsic solubility molecular weight particle size dispersion of solute
factors affecting dissolution rate
transdermal
highly potent, lipid soluble, low MW
rapid absorption because the mucosa is highly vascularized
competitiveness
Prevailing policy environment (e.g. Cheaper Medicines Law, labelling requirements, Pharmacy law) is not conducive to industry growth
innovation
Lack of incentives from the government to both the academe and the pharmaceutical industry to conduct early clinical trials in the country
production and distribution capacity
Constraints in sourcing API finished products and other supplies
resilience
Reliance is further aggravated by challenges and increased costs in supply and distribution
Lack of clear policy to navigate the value chain in times of disasters
ease of doing smooth business
Smooth business processes are hampered by delays in product registration and licensing
policy development and enhancement short term
Industry development as one of the pillars in the new Philippine Medicine Policy
The rate of preferential treatment (currently at 15%) is gradually increased
industry strengthening short term
40% of the volume of pharma products being purchased by DOH is supplied by local manufacturers
Pharmaceutical center at the DOST servicing as a data science hub for the use of the industry and related industries
industry strengthening medium term
Local manufacturing share in volume of the Philippine Pharmaceutical supplies at 50%
pharma industry support system strengthening short term
· DTI pharma industry expert retention and incentive program · DOH capacity for o Operation health technology assessment (HTA) system o Strengthened procurement and supply chain management system (PSCM) o Improved capacity for forecasting, distribution, and use of value-based metrics
pharma industry support system strengthening medium term
· Mechanisms in PPP for technology transfer and knowledge sharing between local and foreign companies are in place · Investments for health data management are in place · FDA is PIC/S accredited
DRUG DEVELOPMENT
The next step is involves transforming a compound from drug candidate to a product approved for marketing by the appropriate regulatory agencies.
chemical development
check chemical stability under various conditions
optimize and scale up synthesis and purification
produce gmp batches as required for biological and clinical testing
pharmaceutical development
develop and deliver formulations for biological testing
develop dosage forms as required
develop special delivery systems
drug metabolism/pharmacokinetics
develop analytical techniques for measuring compound and metabolite concentrations in tissues
develop major metabolites in relevant species, including man
determine pk parameters
safety assessment
safety pharmacology
in vitro toxicology
in vivo toxicology of various species
clinical development
phase 1 (assessment of PK characteristics and side effects in normal volunteers)
phase 2 (dose-finding and tests of efficacy in small groups of patients)
phase 3 (definitive trials of efficacy in large groups of patients, including comparison with standard therapies)
early selection point
Decision to take the drug candidate molecule into early (preclinical development)
decision to develop in man
Entry of compound to Phase 1
full development decision point
After phase 1 and phase 2a are completed
submission decision point
Final decision to apply for registration
exploratory
Aimed a giving a rough quantitative estimate of the toxicity of a compound when given acutely or repeatedly over 2 weeks; no need for GLP
regulatory
o Performed to GLP standards and comprise those that are required by regulatory agencies that will support approval of application
safety pharmacology
This comprises of a series of protocol-driven studies aimed specifically at detecting possible undesirable or dangerous effects of exposure to drug in therapeutic doses
core battery safety test
performed on all compounds intended for systemic use
follow up and supplementary test
performed if on battery test, results mechanisms need to be determined, or if there is a drug-drug interaction.
exploratory toxicology studies
Studies conducted in rodents and non-rodents · Single dose with widely-spaced doses (10,100, 1000 mg/kg) over a 14-day observation.
Usually 4 or 5 doses will be tested.
Dose escalation protocol may be used in which animals treated are administered with increasing doses until signs of toxicity appears or until a dose of 2000mg/kg.
Animals are killed and autopsied to determine target organ toxicity.
Followed by multiple-dose ranging studies in which the drug is given twice daily for 2 weeks.
Limitation: INSUFFICIENT for supporting first human evaluation
genotoxicity
defined as in vitro and in vivo tests designed to detect compounds that induce genetic damage by various mechanisms
Enable hazard identification with respect of damage to DNA and its fixation
Ames test
a. An increase in the number of surviving colonies of S. typhimirium in the absence of histidine denotes mutagenicity.
chronic toxicology studies
The objective of these studies is to look for toxicities after repetitive dosing of the compound when a steady state is reached.
experimental design for chronic toxicity studies
Must be performed under GLP conditions
One rodent plus one non-rodent plus additional species
Separate male and female groups
Average study requires 200 or more rats, 60 dogs
Urine and blood sampling done regularly
Killed after several months, then autopsied or histologic examination.
carcinogenicity testing reproductive or developmental toxicity studies
special tests
carcinogenicity testing
Normally required before a drug can be marketed especially if the compound class belongs to a known class of carcinogens or has chemical features associated with carcinogenicity
Chronic studies show evidence of precancerous changes Compound or metabolites are retained in tissues
reproductive/developmental toxicology studies
The requirement for reproductive toxicology data as a prelude to clinical trials differs from country to country.
General rule: Clinical trials involving women should be preceded by relevant toxicological data.
segment 1 test
fertility and implantation involving treating both males (28 days) and females (14 days) with drug prior to mating
segment 2 test
for embryonic and fetal development, drug being given to female during initial gestational stage.
segment 3
for pre and perinatal development; dosing female rats with drug throughout gestation and lactation.
LD50
o Dose required to kill 50% of a group of experimental animals o Has been largely abandoned as a useful measure of toxicity, and no longer needs to be measured for new compounds
no toxic effect level
o Largest dose in the most sensitive species in a toxicology study of a given duration which produced no observed toxic effect
no observed adverse effect level
o Largest dose causing neither observed tissue toxicity nor undesirable physiological effects such as sedation, seizures, or weight loss
maximum tolerated dose
o Usually applies to long-term studies and represents the largest dose tested that caused no obvious signs of ill-health
no observed effect level
o Represents the threshold for producing any observed pharmacological effect or toxic effect
drug repositioning
Process of uncovering new indication of approved/failed/abandoned compounds. · More practical, less time-consuming and less costly. · 3 approaches:
computational
machine-learning algorithms
experimental
· - provide clear evidences between drug and diseases
mixed approaches
combination of two
aspirin celecoxib dapoxetine duloxetine fingolimod ketoconazole minoxidil raloxifene rituximab sildenafil thalidomide topiramate zidovudine
Examples of drugs successfully repositioned A cute dog doesnt fight kittens, makes rr shoot to the zky HJAHDAHDAHHAHAHAHAHAHAHAHA
conventional/experimental computational mixed approaches
3 approaches in repositioning
molecular modeling
This refers to a data-driven science branch with many algorithms and databases being created or adapted as a response to new data forms (Xia, 2017)
It uses high performance computing used in interpolating laboratory experiments and theory (Aminpour et al., 2019)
high performance computing
used in interpolating lab experiments
structure-based design
Structure is KNOWN
2D/3D conformation
Can be elucidated
It is a multi-disciplinary and iterative process that is well-established in research institution and pharmaceutical industry.
This is used when THE STRUCTURE OF THE TARGET IS KNOWN/AVAILABLE.
Drugs discovered: Zanamivir, Nelfinavir, Aleglitazar
Target Identification
Modeling and visualization of macromolecular structure
Binding site prediction and analysis
Molecular docking
Structure-based virtual screening
Validation of molecular docking
aleglitazar nelfinavir zanamivir
drugs discovered through structure based design
zinc/zinc20
a. Freely available database of commercially available compounds for molecular docking
PubChem
a. Database of small chemical molecules and their biologic activities
ChemSpider
a. All of the chemical structures of compounds
ChemBL
a. Small molecule database contain information of ADMET and binding of huge number of bioactive substances
Drug Bank
a. Comprehensive database with information about the drug, their target, and other useful information
homology modeling
3D images of similar protein
Template structure
Assumption: Two identical structures adopt similar 3D structure.
RasMol, PyMol, Chimera
Visualize macromolecules in atomic levels
· These are visualization tools that play a significant role in viewing and analyzing the predicted and experimentally-determined 3D structures of macromolecules at the atomic level.
PyMol
widely used cross-platform molecular graphics tool for 3D visualization of proteins, small molecules, nucleic acids, electron densities and surface trajectories
RasMol
provides rotation of molecule interactively by viewing molecules in various forms.
PDB databases
Contain fully reviewed and experimentally validated information of protein structure
Focused on amino acids and residues
Residue + candidate
Single worldwide archive of structural data of biologic macromolecules. It includes data obtained from X-ray crystallography and NMR submitted by biologists and biochemist
Text based query
Sequence based query
molecular docking
If the structure of the ligand will fit in receptor binding site
Strength of binding
blind docking
Do not know where it will bind
A: utilize other binding site
Time consuming
flexible rigid
2 types of docking
flexible docking
Ligand and receptor sidechain are kept flexible as well as the binding energy
For induced-fit docking, main chain is moved to integrate the conformational changes of receptor upon ligand binding.
Yields better approach than conventional docking
Disadvantage: may yield poor docking scores due to incorrect ligand binding.
rigid docking
Internal geometry of ligand and receptor is kept fixed during docking simulation.
Successful lead finding: aspartic protease in HIV yielded a candidate inhibitor with higher potency using the DOCK program
structure based virtual screening
Involves docking and screening of a compound database against the drug target, followed by scoring based on binding of free energy.
Ligands are ranked according to their affinity to the target, and the most promising compounds are shown at the top of the list. SBVS methods require that the 3D structure of the target protein be known so that the interactions between the target and each chemical compound can be predicted in silico (Liu et al., 2018).
pose selection docking a decoy set
2 methods of validating molecular docking
pose selection
§ Docking programs are used to re-dock a compound with known conformation and orientation into the target site (Hevener et al., 2019).
docking a decoy set
o inactive or suspected inactive compounds that have been seeded against the target with compounds having known activity (Hevener et al., 2019 and Jain, 2008).
AutoDock
a. Predicts the affinity of binding and poses of small molecules to a 3D structure of the target protein
AutoDock Vina
a. Virtual screening and molecular docking b. Updated version
Glide Schrodinger
Molecular modeling
Hex
a. Docking simulation
MoE
a. Molecular operating environment b. Docking simulations
Ligand based drug design
It is an alternative protocol and plays a tremendous role when the structure of the target protein is unknown or cannot be predicted by available modeling methods.
It uses statistical methods to correlate the activity of the ligand to structural information.
Pharmacophore mapping
QSAR (Quantitative Structure-Activity Relationship)
pharmacophore mapping
abstract description of molecular features necessary for molecular recognition of a ligand by a macromolecule.
features can be used as a query for searching and retrieving potential leads from chemical compound databases.
hydrophobic centroids aromatic rings hydrogen bond donors/acceptors, cations and anions
Examples of pharmacophoric features
quantitative structure activity related
Predicts the biological activity of chemical compounds in drug designing.
It uses mathematical tools to find the relationship between structure and biologic activity.
In here, a QSAR model is built.
2D QSAR
o Uses 2D properties descriptors: steric, electrostatic, hydrophobicity and geometric behavior to interpret biologic activity.
3D QSAR
o Used to overcome limitation of 2D QSAR wherein it is unable to determine correlation between physicochemical properties and 3D spatial arrangement.
2D 3D multidimensional
QSAR models
Computer based field analysis
Based on the concept that biological activity of a small molecule depends on the molecular field.
Uses Lennard Jones and Coulombic potential to calculate steric and electrostatic fields.
Affected by Van der waals
Comparative Molecular Similarity Indices analysis
o More precise and accurate because algorithm is affected by Van der waals.
highest occupied molecuar orbital
o Energy of small molecules that can donate electron during formation of complex
lowest occupied molecular orbital
o Ability of molecules to take electron from associated protein